



REVIEW ARTICLE

**INTEGRATING 3D BIO PRINTING AND PERSONALIZED MEDICINE WITH SCAFFOLD
CONSTRUCTS - THE FUTURE OF ORAL CANCER TREATMENT**

Aravind Kumar Subramanian^{1*}

¹ Prof. Dr Aravind Kumar Subramanian Department of Orthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India

* **Corresponding author:** Prof. Dr Aravind Kumar Subramanian; Department of Orthodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India; e-mail: aravindkumar@saveetha.com

Abstract

The treatment of oral cancer is changing due to the introduction of 3D bioprinting technology, creating personalized models for drug testing and therapy development. Through the precise recreation of TMEs using cells derived from patients, 3D bioprinted models allow for accurate drug screening and personalized treatment approaches, which could improve effectiveness and minimize adverse reactions. Scaffold structures, essential to this method, provide support for delivering drugs to specific targets and for tissue engineering, enhancing drug distribution and assisting with tissue regeneration after surgery. Although there are hurdles in standardizing and getting regulatory approval, combining 3D bioprinting with personalized medicine and scaffold constructs shows potential for enhancing oral cancer treatment with more efficient and customized therapies.

Received: Jul 14, 2024; **Accepted:** Aug 28, 2024; **Published:** Sep 20, 2024

Key-words: Biomimetic models; Targeted drug delivery; Tissue engineering; TME

Introduction

Oral cancer presents challenges in treatment owing to its intricate microenvironment and the prerequisite for specific tailored therapeutic methods. Conventional treatment techniques do not target tumors efficiently and often, while preserving healthy tissues. However, the emergence of 3D bioprinting technology offers positive options for transforming oral cancer treatment through personalized, biomimetic models for drug testing and customized therapy creation. Blending 3D bioprinting with personalized medicine and scaffold constructs has significant potential to enhance oral cancer treatment with more effective and precise methods.

Enhanced drug screening and personalized development

The treatment methods for oral cancer have been changed significantly using 3D Bioprinted models that accurately reconstruct the complex tumor microenvironment (TME).

These sophisticated models include various cell populations, extracellular matrix components, and vascular networks, closely mimicking the complexity as observed in natural tumors.¹ Scientists derive cells from patients that can create customized models which reflect the tumor characteristics of each person exactly, thus permitting for precise testing of drugs and the development of therapy options. This customized strategy greatly enhances the treatment results by categorizing and identifying the most appropriate medications for specific tumor types and patient characteristics, thereby reducing the likelihood of ineffective treatments and undesirable side effects.² 3D bioprinting facilitates to replicate the spatial structure and cell makeup of oral cancers and the process of their interaction with nearby stromal and immune cells. This technology enables the accurate placement of various cell types in a biomimetic scaffold, safeguarding an accurate portrayal of the TME.

3D bioprinted models offer valuable platforms for studying tumor behavior and drug responses *in vitro* by summarizing important aspects like hypoxia, nutrient gradients, and intercellular signaling pathways.³ Additionally, incorporating vascular networks into these models enhances their physiological significance, allowing for the study of drug penetration and effectiveness in perfusable tumor tissues. In general, 3D bioprinted models revolutionize drug discovery and personalized medicine for oral cancer treatment by enabling the creation of targeted therapies customized for each patient's requirements.

Scaffold constructs for targeted drug delivery and tissue engineering

In the field of 3D bioprinting for treating oral cancer, scaffold constructs play a crucial role by providing structural support and facilitating precise tissue formation. These structures offer exciting possibilities for focused drug delivery and tissue engineering uses, transforming treatment methods.³ Mainly, scaffold-based approaches have great promise for accurate drug delivery in treating oral cancer.⁴ Through the design of biocompatible structures, scientists can customize them to gradually release healing substances, aiding in targeted drug distribution to cancer locations and reducing overall bodily harm. This focused strategy shows great potential in improving the effectiveness of treatment while decreasing negative effects linked to traditional systemic drug delivery.² Moreover, scaffold structures play a role in tissue regeneration and wound healing after surgical removal of oral tumors. Through the incorporation of bioactive molecules and growth factors into the scaffolds, researchers can develop environments that promote tissue healing and regrowth. These structures play a vital role in aiding the regenerative process, encouraging the development of effective tissue formations, and enhancing patient results and quality of life.⁴ Through the integration of scaffold-based methods with 3D bioprinting technology, scientists could create complex scaffold structures customized for individual patient requirements.⁵ This individualized method enables the development of scaffolds tailored for specific drug delivery and tissue regeneration, increasing the efficiency of treatment, and enhancing patient recovery.³ Moreover, adding patient-derived cells to these scaffolds increases their physiological

relevance, making it easier to model individual tumor characteristics and responses to treatment. Essentially, scaffold constructs are a key element in combining 3D bioprinting and oral cancer treatment, providing diverse solutions for precise drug delivery and tissue engineering, ultimately promoting personalized medicine methods for enhanced patient results.

Advanced Scaffold Materials for Enhanced Bioprinting Applications

The development of scaffold materials is essential to improving the applications of 3D bioprinting, particularly in the treatment of oral cancer. For tissue engineering, scaffolds offer the structural support necessary for cell adhesion, proliferation, and differentiation. To replicate the TME, mechanical strength, biocompatibility, and degradation rates need to be tuned. Hydrogels, specifically those based on polyethylene glycol (PEG), have demonstrated potential in promoting the development of oral cancer cells while integrating growth factors to promote tissue regeneration.^{3,6,7} The mechanical and bioactive qualities of scaffolds are improved by composite materials, which combine polymers with nanoparticles such as silica, graphene, or gold. This promotes cell adhesion and proliferation.^{5,8,9} Bioceramics, which include hydroxyapatite and calcium phosphate, mimic the bone-tumor interfaces found in oral malignancies.^{4,10,11} Sensitive scaffolds allow for dynamic changes in response to stimuli like as pH or temperature, providing more accurate tumor models. Magnetic nanoparticles and temperature-sensitive hydrogels work particularly well at simulating the changing TME.^{12,13,14}

Overcoming Challenges in 3D Bioprinting for Oral Cancer Treatment

Several obstacles need to be addressed before 3D bioprinting is more therapeutically applicable to the treatment of oral cancer. Accurately reproducing the intricate microenvironment and anatomy of oral cancers is a major challenge. For the purposes of therapy testing and customized medicine, bioprinted models need to be able to represent tumor heterogeneity and invasive characteristics. The problem of repeatable accuracy is apparent in 3D-printed parts such as zirconia crowns. Moreover, including biomarkers such as RFC3 in bioprinted models may enhance the accuracy of head and neck cancer prognoses.^{15,16} Choosing biomaterials with mechanical strength and biocompatibility that simultaneously resemble the TME presents another

difficulty. Accurately reproducing invasive traits, like tumor budding, in bioprinted models is crucial for studying disease progression and therapy response.¹⁷ Suppression-responsive scaffolds and sophisticated printing methods are necessary to solve technical problems like material handling and resolution. Validation and standardization are necessary, though, to guarantee that these models hold up well in a variety of clinical and research settings.^{6,8,9}

Integration of Bioinformatics and AI in Personalized Medicine

Personalized cancer treatment is changing because of the integration of bioinformatics and AI, particularly with 3D bioprinted models. AI uses a wide range of datasets, such as clinical and genetic data, to forecast treatment outcomes tailored to individual patients. Drug screening and treatment planning are improved by this, since 3D bioprinted models that recreate distinct TME are improved.^{12,18} New biomarkers and therapeutic targets are found via bioinformatics, enabling customized treatment approaches.^{10,19} AI-driven models are essential for precise therapy design because they replicate TME interactions.²⁰ Particularly for intricate instances like oral cancer, this synergy holds great promise for individualized cancer management.¹¹

Regulatory Aspects in 3D Bioprinting

Regulations are essential to guaranteeing the efficacy, safety, and moral application of 3D bioprinting in personalized medicine in cancer therapy. Regulations need to keep up with technological advancements and tackle issues including clinical safety hazards, consistency, and quality assurance. The inability of current legislation to keep up with these advancements emphasizes the necessity for specific rules to handle the complexity of 3D bioprinting.^{5,9} To move bioprinted goods into clinical usage while preserving patient safety and ethics, clear regulatory pathways are necessary.^{12,13} The merging of AI and bioinformatics further complicates regulatory requirements.¹⁴

Clinical Translation and Real-World Applications of 3D Bioprinted Models

Significant advancements in 3D bioprinted models, which faithfully replicate TME unique to each patient, are revolutionizing personalized medicine and cancer treatment.^{10,18} By permitting realistic simulations of drug interactions and tumor responses, these models improve drug screening and

enable individualized treatment programs.^{1,6} They also validate novel treatments and increase the efficacy of tailored therapies.^{9,12} In the clinical setting, 3D bioprinting expedites drug discovery, increases treatment precision, and improves patient outcomes.^{13,20} However, before these models reach their full therapeutic potential, technological and regulatory issues need to be resolved.^{3,8}

Future Prospects and Innovations in 3D Bioprinting and Scaffold Constructs

Tissue engineering and regenerative medicine are about to undergo a revolutionary change because to developments in 3D bioprinting and scaffold building. Modern biomaterials and bioprinting methods will enable more accurate and useful scaffold designs, which will produce more complex, personalized tissue models with better mechanical and biological performance.^{8,18} New developments such as multi-material and multi-cellular bioprinting enable the creation of scaffolds with diverse architectures that closely resemble natural tissues.^{10,12} Novelties like living cell-filled bio-inks, growth factors, and extracellular matrix constituents improve scaffold bioactivity and tissue regeneration even further.^{6,19} Dynamic interaction with biological surroundings is made possible by responsive materials and flexible scaffold designs, which enhance tissue restoration.^{14,20} Treatment regimens can be optimized through individualized scaffold designs based on patient data, made possible by the integration of AI and machine learning into bioprinting procedures.^{9,13} The combination of customized medicines, scaffold constructions, and 3D bioprinting presents a promising avenue for treating oral cancer. Customized therapies and accurate drug testing are made possible by patient-specific bioprinted models, which enhance therapeutic results while reducing negative effects. The overall efficacy of treatment is improved by scaffold-based technologies, which facilitate targeted drug administration and tissue regeneration. For complete clinical translation, however, issues like regulatory approval, scalability, and standards need to be resolved. Breaking through these obstacles could lead to important developments in tailored cancer treatment.

Source of funding

The work was not funded.

1. Augustine R, Kalva SN, Ahmad R, et al. 3D Bioprinted cancer models: Revolutionizing personalized cancer therapy. *Transl Oncol.* 2021;14(4):101015. doi:10.1016/j.tranon.2021.101015
2. Safhi AY. Three-Dimensional (3D) Printing in Cancer Therapy and Diagnostics: Current Status and Future Perspectives. *Pharmaceuticals (Basel).* 2022;15(6):678. doi:10.3390/ph15060678
3. Datta P, Dey M, Ataie Z, Unutmaz D, Ozbolat IT. 3D bioprinting for reconstituting the cancer microenvironment. *NPJ Precis Oncol.* 2020;4:18. doi:10.1038/s41698-020-0121-2
4. Li J, Liang D, Chen X, Sun W, Shen X. Applications of 3D printing in tumor treatment. *Biomedical Technology.* 2024;5:1-3.
5. Almela T, Tayebi L, Moharamzadeh K. 3D bioprinting for in vitro models of oral cancer: Toward development and validation. *Bioprinting.* 2021;22:e00132. doi:10.1016/j.bprint.2021.e00132
6. Parodi I, Di Lisa D, Pastorino L, Scaglione S, Fato MM. 3D bioprinting as a powerful technique for recreating the TME. *Gels.* 2023 Jun 12;9(6):482.
7. Haleem A, Javaid M, Vaishya R. 3D printing applications for the treatment of cancer. *Clinical Epidemiology and Global Health.* 2020 Dec 1;8(4):1072-6.
8. Liu N, Zhang X, Guo Q, Wu T, Wang Y. 3D bioprinted scaffolds for tissue repair and regeneration. *Frontiers in Materials.* 2022 Jul 7;9:925321.
9. Sharma R, Perez MR, da Silva VA, Thomsen J, Bhardwaj L, Andrade TA, Alhussan A, Willerth SM. 3D bioprinting complex models of cancer. *Biomaterials Science.* 2023;11(10):3414-30.
10. Germain N, Dhayer M, Dekioug S, Marchetti P. Current advances in 3D bioprinting for cancer modeling and personalized medicine. *International journal of molecular sciences.* 2022 Mar 22;23(7):3432.
11. Igawa K, Izumi K, Sakurai Y. Development of the Follow-Up Human 3D Oral Cancer Model in Cancer Treatment. *BioTech.* 2023 May 11;12(2):35.
12. Khorsandi D, Rezayat D, Sezen S, Ferrao R, Khosravi A, Zarepour A, Khorsandi M, Hashemian M, Iravani Bioprinting in Cancer Research: How Does the Future Look Like?. *J Mater Chem B.* 2024,12, 4584-12.
13. Mohanprasanth A, Saravanan M. Advancements in cancer research: 3D bioprinting as an optimal oral tumor model. *Oral Oncology Reports.* 2024 Jan 17:100174.
14. Amiri E, Sanjarnia P, Sadri B, Jafarkhani S, Khakbiz M. Recent advances and future directions of 3D to 6D printing in brain cancer treatment and neural tissue engineering. *Biomed. Mater.* 2023;18:052005.
15. Mosaddad SA, Peláez J, Panadero RA, Ghodsi S, Akhlaghian M, Suárez MJ. Do 3D-printed and milled tooth-supported complete monolithic zirconia crowns differ in accuracy and fit? A systematic review and meta-analysis of in vitro studies. *J Prosthet Dent.* 2024 May 20:S0022-3913(24)00283-X. doi: 10.1016/j.prosdent.2024.04.010. Epub ahead of print. PMID: 38772783.
16. Avs KR, Pandi C, Kannan B, Pandi A, Jayaseelan VP, Arumugam P. RFC3 serves as a novel prognostic biomarker and target for head and neck squamous cell carcinoma. *Clin Oral Investig.* 2023 Nov;27(11):6961-6969. doi: 10.1007/s00784-023-05316-4. Epub 2023 Oct 20. PMID: 37861747.
17. Selvaraj FM, Joseph AP, Pillai VR, Ramani P, Pazhani J, Mony V. Significance of tumour budding and invasive characteristics in grading of oral squamous cell carcinoma. *J Oral Maxillofac Pathol.* 2023 Oct-Dec;27(4):642-648. doi: 10.4103/jomfp.jomfp_410_23. Epub 2023 Dec 20. PMID: 38304506; PMCID: PMC10829472.
18. Almela T, Tayebi L, Moharamzadeh K. 3D Bioprinting for In Vitro Models of Oral Cancer: Toward Development and Validation. *Bioprinting.* 2021 Jun;22:e00132. doi: 10.1016/j.bprint.2021.e00132. PMID: 34368488; PMCID: PMC8341396.
19. Gupta D, Negi NP. 3D bioprinting: Printing the future and recent advances. *Bioprinting.* 2022 Aug 1;27:e00211.
20. Zhang Y. 3D Printing for Cancer Diagnosis: What Unique Advantages Are Gained?. *ACS Materials Au.* 2023 Aug 28;3(6):620-35.